Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patients | 1 | 2023 | 69 | 0.840 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2023 | 90 | 0.830 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 177 | 0.790 |
Why?
|
| Referral and Consultation | 2 | 2023 | 383 | 0.750 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2015 | 178 | 0.650 |
Why?
|
| Stents | 7 | 2014 | 657 | 0.620 |
Why?
|
| Coronary Artery Disease | 6 | 2018 | 696 | 0.620 |
Why?
|
| Acute Coronary Syndrome | 2 | 2016 | 195 | 0.580 |
Why?
|
| Renal Artery Obstruction | 3 | 2012 | 29 | 0.540 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2011 | 134 | 0.470 |
Why?
|
| Patient Selection | 4 | 2011 | 592 | 0.420 |
Why?
|
| Iliac Artery | 1 | 2011 | 44 | 0.380 |
Why?
|
| Pacemaker, Artificial | 2 | 2022 | 157 | 0.370 |
Why?
|
| Endovascular Procedures | 2 | 2011 | 366 | 0.360 |
Why?
|
| Aortic Diseases | 1 | 2011 | 113 | 0.360 |
Why?
|
| Vascular Surgical Procedures | 1 | 2011 | 168 | 0.350 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2016 | 73 | 0.340 |
Why?
|
| Endarterectomy, Carotid | 3 | 2014 | 110 | 0.300 |
Why?
|
| Heart Neoplasms | 1 | 2008 | 33 | 0.300 |
Why?
|
| Lipoma | 1 | 2008 | 24 | 0.300 |
Why?
|
| Cardiac Catheterization | 6 | 2022 | 419 | 0.290 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2017 | 137 | 0.290 |
Why?
|
| Contrast Media | 2 | 2022 | 595 | 0.280 |
Why?
|
| Treatment Outcome | 15 | 2023 | 7029 | 0.260 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2016 | 373 | 0.260 |
Why?
|
| Microbubbles | 2 | 2022 | 8 | 0.250 |
Why?
|
| Humans | 36 | 2023 | 68618 | 0.250 |
Why?
|
| No-Reflow Phenomenon | 2 | 2018 | 3 | 0.250 |
Why?
|
| Saphenous Vein | 2 | 2016 | 61 | 0.250 |
Why?
|
| Blood Pressure Determination | 2 | 2022 | 152 | 0.230 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2022 | 450 | 0.230 |
Why?
|
| Coronary Artery Bypass | 2 | 2016 | 218 | 0.220 |
Why?
|
| Carotid Stenosis | 3 | 2014 | 163 | 0.220 |
Why?
|
| Coronary Occlusion | 1 | 2023 | 12 | 0.220 |
Why?
|
| Aspirin | 3 | 2016 | 295 | 0.210 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 82 | 0.210 |
Why?
|
| Myocardial Infarction | 4 | 2015 | 807 | 0.210 |
Why?
|
| Arterial Pressure | 1 | 2022 | 47 | 0.200 |
Why?
|
| Drug-Eluting Stents | 2 | 2014 | 51 | 0.200 |
Why?
|
| Angioplasty | 2 | 2014 | 118 | 0.200 |
Why?
|
| Coronary Angiography | 5 | 2018 | 866 | 0.200 |
Why?
|
| Sirolimus | 2 | 2014 | 118 | 0.190 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2022 | 174 | 0.190 |
Why?
|
| Carotid Artery Diseases | 2 | 2011 | 83 | 0.190 |
Why?
|
| Electrocardiography | 3 | 2021 | 601 | 0.190 |
Why?
|
| Angina Pectoris | 2 | 2018 | 61 | 0.180 |
Why?
|
| Nicardipine | 2 | 2018 | 21 | 0.180 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2021 | 100 | 0.180 |
Why?
|
| Aged | 17 | 2018 | 14862 | 0.180 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 222 | 0.180 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 110 | 0.170 |
Why?
|
| Ultrasonography | 2 | 2022 | 453 | 0.170 |
Why?
|
| Risk Assessment | 7 | 2018 | 2007 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 239 | 0.170 |
Why?
|
| Aortic Valve | 2 | 2021 | 249 | 0.170 |
Why?
|
| Male | 18 | 2023 | 37321 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 212 | 0.170 |
Why?
|
| Heart Rate | 1 | 2021 | 568 | 0.160 |
Why?
|
| Retrospective Studies | 12 | 2021 | 7277 | 0.160 |
Why?
|
| Vasodilator Agents | 2 | 2017 | 138 | 0.150 |
Why?
|
| Nerve Block | 1 | 2018 | 55 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 438 | 0.150 |
Why?
|
| Coronary Vasospasm | 1 | 2017 | 2 | 0.150 |
Why?
|
| Nitroglycerin | 1 | 2017 | 20 | 0.150 |
Why?
|
| Ventricular Function | 1 | 2017 | 93 | 0.140 |
Why?
|
| Catheters | 2 | 2022 | 39 | 0.140 |
Why?
|
| Embolic Protection Devices | 1 | 2016 | 12 | 0.140 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2017 | 38 | 0.140 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 100 | 0.140 |
Why?
|
| Coronary Stenosis | 2 | 2017 | 246 | 0.140 |
Why?
|
| Mitral Valve | 1 | 2017 | 166 | 0.140 |
Why?
|
| Image Enhancement | 1 | 2017 | 143 | 0.140 |
Why?
|
| Anticoagulants | 3 | 2016 | 356 | 0.140 |
Why?
|
| Risk Factors | 8 | 2016 | 5731 | 0.140 |
Why?
|
| Heart Ventricles | 2 | 2017 | 738 | 0.140 |
Why?
|
| Thrombosis | 2 | 2014 | 218 | 0.130 |
Why?
|
| Aged, 80 and over | 9 | 2018 | 4848 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 164 | 0.130 |
Why?
|
| Ischemia | 3 | 2012 | 229 | 0.130 |
Why?
|
| Shock, Cardiogenic | 1 | 2015 | 23 | 0.130 |
Why?
|
| Coronary Circulation | 2 | 2018 | 136 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2014 | 140 | 0.120 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 123 | 0.110 |
Why?
|
| Constriction, Pathologic | 2 | 2011 | 236 | 0.110 |
Why?
|
| Hypertension, Renovascular | 2 | 2012 | 47 | 0.110 |
Why?
|
| Radiography | 2 | 2011 | 572 | 0.110 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2012 | 35 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 424 | 0.100 |
Why?
|
| Female | 16 | 2018 | 38074 | 0.100 |
Why?
|
| Middle Aged | 12 | 2018 | 21147 | 0.100 |
Why?
|
| Reperfusion | 1 | 2012 | 78 | 0.100 |
Why?
|
| Hemorrhage | 2 | 2017 | 328 | 0.090 |
Why?
|
| Kidney | 3 | 2012 | 945 | 0.090 |
Why?
|
| Leg | 1 | 2011 | 191 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 50 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 1465 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2011 | 276 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2010 | 153 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 166 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1851 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2023 | 384 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2011 | 504 | 0.070 |
Why?
|
| Incidence | 3 | 2021 | 1603 | 0.070 |
Why?
|
| Warfarin | 1 | 2007 | 93 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2007 | 118 | 0.070 |
Why?
|
| Reoperation | 2 | 2022 | 467 | 0.070 |
Why?
|
| Time Factors | 5 | 2014 | 4655 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 940 | 0.060 |
Why?
|
| Registries | 3 | 2014 | 733 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2005 | 51 | 0.060 |
Why?
|
| Recurrence | 3 | 2014 | 948 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 649 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 122 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2018 | 2358 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 772 | 0.050 |
Why?
|
| Robotic Surgical Procedures | 1 | 2022 | 49 | 0.050 |
Why?
|
| United States | 4 | 2016 | 7367 | 0.050 |
Why?
|
| Global Health | 1 | 2021 | 136 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2021 | 301 | 0.050 |
Why?
|
| Atherosclerosis | 2 | 2013 | 204 | 0.050 |
Why?
|
| Injections, Intra-Arterial | 1 | 2018 | 30 | 0.040 |
Why?
|
| Subclavian Artery | 1 | 2018 | 30 | 0.040 |
Why?
|
| Echocardiography | 1 | 2021 | 515 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 850 | 0.040 |
Why?
|
| Acoustics | 1 | 2017 | 20 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 49 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2017 | 60 | 0.030 |
Why?
|
| Fluorocarbons | 1 | 2017 | 82 | 0.030 |
Why?
|
| Nitrates | 1 | 2016 | 61 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3259 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 109 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2022 | 1451 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2017 | 250 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 152 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 500 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 506 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 275 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 567 | 0.030 |
Why?
|
| Adult | 3 | 2018 | 21403 | 0.030 |
Why?
|
| Software | 1 | 2017 | 418 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 59 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 338 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 117 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 2093 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 425 | 0.030 |
Why?
|
| Tunica Intima | 1 | 2013 | 59 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2013 | 89 | 0.030 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2012 | 9 | 0.030 |
Why?
|
| Receptor, PAR-1 | 1 | 2012 | 30 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 167 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 2012 | 37 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 458 | 0.030 |
Why?
|
| Drug Design | 1 | 2012 | 107 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 563 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 111 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2077 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1864 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 130 | 0.020 |
Why?
|
| Stroke | 2 | 2014 | 2163 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1745 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2010 | 31 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2010 | 63 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2011 | 186 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2009 | 25 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 658 | 0.020 |
Why?
|
| Nicorandil | 1 | 2009 | 2 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 252 | 0.020 |
Why?
|
| Verapamil | 1 | 2009 | 30 | 0.020 |
Why?
|
| Nitroprusside | 1 | 2009 | 42 | 0.020 |
Why?
|
| Diltiazem | 1 | 2009 | 26 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 172 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 181 | 0.020 |
Why?
|
| Adenosine | 1 | 2009 | 165 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 291 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2009 | 159 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 498 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 931 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1420 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 378 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2009 | 705 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2007 | 289 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 792 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2007 | 249 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1196 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 20881 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2324 | 0.010 |
Why?
|